Clinical data | |
---|---|
Other names | BI 201335 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C40H49BrN6O9S |
Molar mass | 869.83 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.
Mechanism of action
Faldaprevir is a hepatitis C virus protease inhibitor.
Studies
Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.
Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.
References
- Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov
- "Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.
- Kanda T, Yokosuka O, Omata M (March 2015). "Faldaprevir for the treatment of hepatitis C". International Journal of Molecular Sciences. 16 (3): 4985–96. doi:10.3390/ijms16034985. PMC 4394460. PMID 25749475.
RNA virus antivirals (primarily J05, also S01AD and D06BB) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Hepatitis C |
| ||||||||
Hepatitis D | |||||||||
Picornavirus | |||||||||
Anti-influenza agents | |||||||||
Multiple/general |
| ||||||||
|